In this episode, Paul Dabrowski, CEO of Synthego, and Robert Deans, CSO of Synthego, discuss the CRISPR silver linings of 2020 and predict the directions and milestones for gene editing in 2021.
The COVID-19 pandemic is a unique situation for lab scientists, many of whose work has come to a standstill. Hamid Ghanadaan, CEO of Linus, discusses the impact of COVID-19 on science and the next steps for scientists, based on their survey of >1000 scientists.
The mission of Indee Labs, a Berkeley biotech, is to deliver CRISPR reagents into cells using microfluidics for developing affordable cell and gene therapies in the future. We interviewed Ryan Pawell, Founder and CEO of Indee Labs, about the concept of using microfluidics for CRISPR delivery, their mission and ongoing projects, and the convergence of engineering and biology for building scalable platforms.
What is the process to make a science film? In this episode, Sarah Goodwin and Elliot Kirschner, producers of Human Nature, a documentary on CRISPR, offer glimpses into making of the film.
Shondra Miller shares her experience of starting a shared genome engineering resource at the St. Jude Children's Research Hospital. Learn more about her research projects and her views on the past, present, and future of the genome editing field in this podcast episode.
Dr. Bill Skarnes, Professor at The Jackson Laboratory, chats about how CRISPR edited stem cells are becoming a gold standard to study gene function and disease modeling.
Rebecca Shapiro, Assistant Professor at the University of Guelph, talks about CRISPR genome editing in fungal pathogens to understand their disease-causing mechanism. Her lab also works on gene drives in fungi for studying large scale genetic interactions and developing ways for treating fungal biofilms.
In this interview, Paul Dabrowski, CEO of Synthego, talks about how Synthego got started, his mantra behind leading the company, and future directions. He also offers insights into Synthego’s unique capabilities—the powerful combination of engineering and biology that enable scaling.
CRISPR has great potential in therapeutics, but CRISPR delivery in vivo remains a challenge. Researcher Dana Foss discusses her lab’s novel approach for specific delivery of CRISPR components in cells and tissues.
CRISPR is going beyond gene editing into a new area: diagnostics. Omar Abudayyeh and Jonathan Gootenberg, co-founders of SHERLOCK Biosciences, talk about the present advances and future of CRISPR diagnostics.